The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Soft Tissue Sarcoma Market Projected To Reach By 2030?
The soft tissue sarcoma market size has shown significant expansion in recent years. It is anticipated to increase from $3.41 billion in 2025 to $3.7 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.4%. This historical growth can be linked to several factors, including advancements in cancer diagnostics, increased funding for oncology research, heightened awareness of rare cancers, the accessibility of chemotherapy, and improvements in surgical procedures.
The soft tissue sarcoma market is predicted to undergo robust expansion in the coming years. This sector is expected to reach a value of $5.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.7%. The projected increase within this period is attributable to elements like new drug approvals, the widening scope of immunotherapy, advancements in molecular testing, the rising demand for tailored treatments, and improvements in oncology infrastructure. Significant trends for the forecast duration include an increased application of targeted therapies, more prevalent genetic profiling, the expansion of combination treatment protocols, a surge in clinical trial enrollment, and the greater embrace of multidisciplinary care.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12211&type=smp
Which Primary Drivers Are Impacting The Soft Tissue Sarcoma Market Growth?
The anticipated increase in cancer cases is projected to drive expansion within the soft tissue sarcoma market in the coming period. Cancer encompasses a wide range of diseases originating in any organ or tissue, characterized by the unchecked proliferation of abnormal cells that surpass their normal confines, either spreading to distant organs or infiltrating adjacent body areas. This escalating incidence of cancer elevates the demand for diagnostic methods, treatment protocols, and supportive care options, all designed to address the specific needs of individuals afflicted with various forms of cancer or sarcoma, thereby stimulating the soft tissue sarcoma market. As an illustration, in July 2024, data from the Australian Institute of Health and Welfare, an Australian government body, indicated that approximately 165,000 Australians received a new cancer diagnosis in 2023, translating to more than 450 cases daily, with males accounting for roughly 55% of these diagnoses. Consequently, the rising prevalence of cancer is a key factor propelling the expansion of the soft tissue sarcoma market.
What Are The Key Segment Divisions In The Soft Tissue Sarcoma Market Segment Structure?
The soft tissue sarcoma market covered in this report is segmented –
1) By Treatment: Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Other Treatments
2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
3) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users
Subsegments:
1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies, Immunotherapy Agents
2) By Chemotherapy: Doxorubicin, Ifosfamide, Gemcitabine, Other Chemotherapeutic Agents
3) By Anti-Angiogenesis Drugs: Bevacizumab, Pazopanib, Axitinib, Other Anti-Angiogenesis Agents
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy
5) By Other Treatments: Surgery, Clinical Trials, Supportive Care
Which Trends Are Shaping Growth In The Soft Tissue Sarcoma Market?
Major companies active in the soft tissue sarcoma market are prioritizing the creation of innovative products to bolster their market presence. For instance, in November 2023, Mercy, a US-based not-for-profit Catholic healthcare organization, introduced an innovative AI-powered texting program known as The Chen Chemotherapy Model, intended to proactively prevent hospitalizations linked to chemotherapy. This program utilizes a smart texting platform that sends daily messages to chemotherapy patients seven days a week, excluding weekends and holidays. The texts present a list of symptoms, including diarrhea, pain, fever, fatigue, nausea or vomiting, or no symptoms. Patients can select and rate their symptoms, and based on their responses, this information may be escalated to their healthcare provider. The objective is to identify potential issues early and intervene before symptoms worsen, highlighting Mercy’s commitment to leveraging technology for improved patient care in chemotherapy.
Which Organizations Are Engaged In The Soft Tissue Sarcoma Market?
Major companies operating in the soft tissue sarcoma market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Lupin Ltd., Philogen S.p.A., Taiho Pharmaceutical Co.Ltd., Nanobiotix S.A.
Get The Full Soft Tissue Sarcoma Market Report:
https://www.thebusinessresearchcompany.com/report/soft-tissue-sarcoma-global-market-report
Which Region Leads The Soft Tissue Sarcoma Market In Terms Of Market Share?
North America was the largest region in the soft tissue sarcoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the soft tissue sarcoma market report during the forecast period. The regions covered in the soft tissue sarcoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Soft Tissue Sarcoma Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/soft-tissue-sarcoma-global-market-report
Browse Through More Reports Similar to the Global Soft Tissue Sarcoma Market 2026, By The Business Research Company
Sarcoma Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report
Central Nervous System Lymphoma Treatment Market Report
Soft Tissue Repair Market Report
https://www.thebusinessresearchcompany.com/report/soft-tissue-repair-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model